Max Robotics — Global Service Robot Directory + US Certification

About

Shohei Koide is a leading figure in protein engineering and antibody discovery, best known for pioneering high-throughput platforms that transform how recombinant antibodies are generated and validated. His work addresses a critical bottleneck in biomedical research: the need for renewable, sequence-defined antibodies. Koide’s landmark 2015 paper, with 120 citations, describes an industrialized platform that produced validated recombinant antibodies for 346 transcription factors, demonstrating a scalable solution to replace traditional, non-renewable monoclonal antibodies. This breakthrough ensures permanent reagent access and reproducibility. Complementing this, his 2015 study on scalable high-throughput selection from phage-displayed synthetic antibody libraries (33 citations) advances methods to meet the growing demand for antibodies suited to both basic and clinical applications. By moving beyond conventional hybridoma technologies, Koide has established a new paradigm for antibody generation—one that is rapid, renewable, and adaptable. His contributions are foundational for researchers seeking robust, high-quality reagents, and his work continues to shape the future of proteomics, structural biology, and therapeutic development.